Metastatic Hepatocellular Carcinoma Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight's, "Metastatic Hepatocellular Carcinoma Pipeline Insight, 2026" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Metastatic Hepatocellular Carcinoma pipeline landscape. It covers the Metastatic Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Hepatocellular Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Metastatic Hepatocellular Carcinoma research @ Metastatic Hepatocellular Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/metastatic-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Metastatic Hepatocellular Carcinoma Pipeline Report

* On March 18, 2026- Coherus Oncology Inc . announced a Phase 2 trial composed of an open label Lead-In followed by a Randomized Phase designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo (inactive substance) in combination with atezolizumab plus bevacizumab in patients with first-line advanced or metastatic HCC.
* On March 09, 2026, AstraZeneca initiated a Phase I/II study will evaluate the safety, tolerability, antitumour activity, cellular kinetics, pharmacodynamics, and immunogenicity of AZD5851 in adult participants with GPC3+ advanced/recurrent HCC, where at least one line of prior therapy has failed/or was intolerable, or participant/investigator decision.
* DelveInsight's Metastatic Hepatocellular Carcinoma pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Metastatic Hepatocellular Carcinoma treatment.
* The leading Metastatic Hepatocellular Carcinoma Companies such as Ionis Pharmaceuticals, CStone Pharmaceuticals, Coherus BioSciences, Tvardi Therapeutics, Sapience Therapeutics, Inc., Eureka Therapeutics Inc., Krystal Biotech, Inc., Replimune Inc., Beijing Syngentech Co., Ltd., Boehringer Ingelheim, AbbVie, Chugai Pharmaceutical, GenVivo, Inc., Suzhou Kintor Pharmaceutical Inc., Shanghai Henlius Biotech and others.
* Promising Metastatic Hepatocellular Carcinoma Pipeline Therapies such as Huaier Granule, Lenvatinib, Tislelizumab, GC33, Atezolizumab, Bevacizumab, Tiragolumab, Relatlimab, Nivolumab, Bevacizumab , and others.

Download for updates and be a part of the revolution in cancer care @ Metastatic Hepatocellular Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/metastatic-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Metastatic Hepatocellular Carcinoma Overview

Metastatic hepatocellular carcinoma (HCC) refers to the spread of primary liver cancer to other parts of the body, typically through the bloodstream or lymphatic system. Hepatocellular carcinoma originates in the liver cells and is one of the most common types of liver cancer. When it metastasizes, it often spreads to the lungs, bones, lymph nodes, or other organs. Metastatic HCC presents significant challenges in terms of treatment and prognosis, as it is usually diagnosed at an advanced stage when the cancer has already spread beyond the liver. Signs and symptoms of metastatic HCC can vary depending on the location and extent of metastasis. Common symptoms include abdominal pain or discomfort, weight loss, loss of appetite, nausea, vomiting, jaundice (yellowing of the skin and eyes), fatigue, and weakness. If the cancer has spread to the lungs, patients may experience difficulty breathing or coughing up blood. Bone metastases can cause bone pain and fractures, while involvement of the brain may lead to neurological symptoms such as headaches, seizures, or weakness in limbs.

Metastatic Hepatocellular Carcinoma Emerging Drugs Profile

* CS1003: CStone Pharmaceuticals

CS1003 or Nofazinlimab is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed in solid tumors. Nofazinlimab shows comparable high binding affinities to the PD-1 of humans, cynomolgus monkey, and mouse, and can block the interaction of PD-1 with its ligands PD-L1 and PD-L2. The U.S. FDA has granted nofazinlimab Orphan Drug Designation (ODD) in July 2020 for the treatment of patients with HCC. CStone formed a strategic collaboration agreement with EQRx, under which EQRx licensed the exclusive rights to two immuno-oncology assets, sugemalimab and nofazinlimab, for development and commercialization outside of Greater China. CStone retains rights to nofazinlimab in Greater China, where it can continue to pursue development as a monotherapy or as part of its combination strategy for this drug. Currently, the drug is in Phase III stage of its development for the treatment of hepatocellular carcinoma.

* Casdozokitug: Coherus BioSciences

Casdozokitug is a human anti-IL-27 antibody designed to inhibit the activity of this immune regulatory cytokine. The company is focused on developing casdozokitug in particular tumor types where IL-27 secreted from macrophages appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with immune checkpoint inhibitors. Preclinical studies have shown that treatment with casdozokitug blocks the immunosuppressive biologic effects of IL-27, resulting in immune cell activation in combination with other cancer therapies including anti-PD-1 therapy, as well as anti-tumor effects. Casdozokitug has been granted Orphan Drug designation and Fast Track designation for the treatment of refractory hepatocellular carcinoma from the FDA. It is the first IL-27 antibody to enter the clinic. Currently, the drug is in Phase II stage of its development for the treatment of hepatocellular carcinoma.

* TTI-101: Tvardi Therapeutics

TTI-101 is an orally bioavailable, small-molecule inhibitor of signal transducer and activator of transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis. Preclinically, TTI-101 has demonstrated an excellent pharmacokinetic profile, potency in inhibiting STAT3 activation, and efficacy in inhibiting tumor growth in xenograft and syngeneic tumor models. In its first-in-man Phase 1 trial conducted in patients with relapsed/refractory tumors, TTI-101 monotherapy was well-tolerated and had clinical activity across a broad range of tumors including multiple durable radiographic objective responses. Currently, the drug is in Phase I/II stage of its development for the treatment of hepatocellular carcinoma.

* ST316: Sapience Therapeutics, Inc.

ST316, a first-in-class antagonist of the interaction between -catenin and its co-activator BCL9, is being evaluated in the Phase I portion of a Phase I-II clinical study in patients with selected advanced unresectable and metastatic solid tumors. ST316-101 is an open-label, two-part study. The Phase I dose-escalation portion of the study is designed to determine the safety, tolerability, PK, and PD of ST316 in patients with selected advanced solid tumors likely to harbor abnormalities of the Wnt/-catenin signaling pathway. The Phase II dose-expansion portion aims to continue to assess the safety of ST316 as well as proof of concept in four specific tumor types known to harbor abnormalities of the Wnt/-catenin signaling pathway. Currently, the drug is in Phase I/II stage of its development for the treatment of hepatocellular carcinoma.

The Metastatic Hepatocellular Carcinoma Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Hepatocellular Carcinoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Hepatocellular Carcinoma Treatment.
* Metastatic Hepatocellular Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Metastatic Hepatocellular Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Hepatocellular Carcinoma market.

Learn more about Metastatic Hepatocellular Carcinoma Drugs opportunities in our groundbreaking Research @ Metastatic Hepatocellular Carcinoma Unmet Needs [https://www.delveinsight.com/sample-request/metastatic-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Metastatic Hepatocellular Carcinoma Companies

Ionis Pharmaceuticals, CStone Pharmaceuticals, Coherus BioSciences, Tvardi Therapeutics, Sapience Therapeutics, Inc., Eureka Therapeutics Inc., Krystal Biotech, Inc., Replimune Inc., Beijing Syngentech Co., Ltd., Boehringer Ingelheim, AbbVie, Chugai Pharmaceutical, GenVivo, Inc., Suzhou Kintor Pharmaceutical Inc., Shanghai Henlius Biotech and others.

Metastatic Hepatocellular Carcinoma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Metastatic Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Stay informed about how we're transforming the future of oncology @ Metastatic Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/metastatic-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Metastatic Hepatocellular Carcinoma Pipeline Report

* Coverage- Global
* Metastatic Hepatocellular Carcinoma Companies- Ionis Pharmaceuticals, CStone Pharmaceuticals, Coherus BioSciences, Tvardi Therapeutics, Sapience Therapeutics, Inc., Eureka Therapeutics Inc., Krystal Biotech, Inc., Replimune Inc., Beijing Syngentech Co., Ltd., Boehringer Ingelheim, AbbVie, Chugai Pharmaceutical, GenVivo, Inc., Suzhou Kintor Pharmaceutical Inc., Shanghai Henlius Biotech and others.
* Metastatic Hepatocellular Carcinoma Pipeline Therapies- Huaier Granule, Lenvatinib, Tislelizumab, GC33, Atezolizumab, Bevacizumab, Tiragolumab, Relatlimab, Nivolumab, Bevacizumab , and others.
* Metastatic Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Metastatic Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Metastatic Hepatocellular Carcinoma Pipeline on our website @ Metastatic Hepatocellular Carcinoma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/metastatic-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Metastatic Hepatocellular Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Metastatic Hepatocellular Carcinoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* CS1003: CStone Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Casdozokitug: Coherus BioSciences
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* ST316: Sapience Therapeutics, Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Metastatic Hepatocellular Carcinoma Key Companies
* Metastatic Hepatocellular Carcinoma Key Products
* Metastatic Hepatocellular Carcinoma- Unmet Needs
* Metastatic Hepatocellular Carcinoma- Market Drivers and Barriers
* Metastatic Hepatocellular Carcinoma- Future Perspectives and Conclusion
* Metastatic Hepatocellular Carcinoma Analyst Views
* Metastatic Hepatocellular Carcinoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-hepatocellular-carcinoma-clinical-trial-pipeline-expands-as-20-companies-driving-innovation-in-the-therapeutics-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-hepatocellular-carcinoma-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.